Cardiff Oncology Inc Stock Price, News & Analysis

Cardiff Oncology, Inc. (Nasdaq: CRDF) announced significant progress in cancer therapies, presenting promising preclinical data at AACR. Notably, onvansertib combined with olaparib showed a statistically significant survival benefit in ovarian cancer models. In metastatic castration-resistant prostate cancer (mCRPC), updated clinical results indicated increasing disease control rates with higher onvansertib doses, reaching 75% in the most intense treatment group. As of June 30, 2022, the company reported $122 million in cash, with an increase in operating expenses driven by R&D efforts and staff expansion.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, held at The St. Regis New York. The company aims to leverage its expertise in PLK1 inhibition to develop novel cancer therapies, particularly focusing on its lead asset, onvansertib, which targets treatment-resistant cancers. A pre-recorded fireside chat will be available on-demand starting July 11, 2022. For more details, visit Cardiff Oncology's website.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference in Miami, Florida, from May 23-26, 2022. The fireside chat is scheduled for May 24, 2022, at 5:00 PM ET. The event is a platform for the company to discuss its innovative therapies, particularly its lead asset, onvansertib, aimed at overcoming treatment resistance in various cancers. A replay will be available on their website following the event.

Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 results for its lead KRAS-mutated metastatic colorectal cancer program, showcasing an objective response rate (ORR) of 34% compared to historical controls of 5-13%. Additionally, Phase 2 data from its metastatic castration-resistant prostate cancer trial indicated that 75% of patients on the highest dose achieved disease control. The company holds approximately $129.4 million in cash as of March 31, 2022, with increased operating expenses attributed to development efforts for onvansertib. These results position Cardiff for future growth and advancement in oncology.

Cardiff Oncology (Nasdaq: CRDF) announced the departure of its Chief Medical Officer, Katherine L. Ruffner, M.D., effective April 22, 2022. Dr. Ruffner will assist during the transition, while Sandra L. Silberman, M.D., Ph.D., will serve as the interim senior medical advisor overseeing clinical trials. The company's clinical development efforts for its primary drug candidate, onvansertib, remain on track. CEO Mark Erlander expressed gratitude for Dr. Ruffner's contributions and optimism for the year ahead.

Cardiff Oncology announced updated clinical data from its Phase 2 trial evaluating onvansertib combined with abiraterone and prednisone for metastatic castration-resistant prostate cancer (mCRPC). The trial shows increased disease control rates with higher dose densities of onvansertib—from 29% to 45% for PSA stabilization and 53% to 75% for radiographic stable disease. Median progression-free survival increased from 4.1 months to 13.2 months in patients receiving onvansertib. Genomic analysis suggests sensitivity to the combination treatment correlates with mutations in MTOR and PTEN.

Cardiff Oncology (Nasdaq: CRDF) announced promising results from preclinical studies at the AACR Annual Meeting, showcasing that the combination of onvansertib and the PARP inhibitor olaparib significantly improves survival in PARPi-resistant ovarian cancer models. The studies demonstrated that this combination therapy was well tolerated and effective against various PDX models, including both BRCA1-mutant and wild-type variants. These findings support further investigation into this treatment approach for overcoming resistance to PARP inhibitors in clinical settings.

Cardiff Oncology, a clinical-stage biotechnology company, announced that CEO Mark Erlander will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The fireside chat is scheduled for March 28 at 2:30 PM ET. The conference will be hosted by Maxim Group LLC and streamed live on M-Vest. Additionally, Dr. Erlander will provide a pre-recorded overview of the company's clinical and corporate strategy. Cardiff Oncology focuses on developing therapies targeting cancers using its lead asset, onvansertib, a PLK1 inhibitor. For more information, visit their website.

Cardiff Oncology (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the AACR Annual Meeting from April 8-13, 2022 in New Orleans. The presentations focus on their lead asset, onvansertib, a promising PLK1 inhibitor. The first abstract discusses biomarkers for mCRPC patients receiving onvansertib with abiraterone, while the second highlights combination therapy's potential against PARP inhibitor resistance. These findings aim to advance treatment options for cancer patients.